FDA Approves ONDANSETRON HYDROCHLORIDE — Onesource Specialty Pharma Limited

# FDA Approves Ondansetron Hydrochloride Intramuscular Injection for Onesource Specialty Pharma Onesource Specialty Pharma Limited received FDA approval for its generic ondansetron hydrochloride intramuscular injection (ANDA078257), expanding the competitive landscape in the antiemetic market and potentially reducing treatment costs for patients requiring injectable nausea and vomiting management. The approval positions Onesource to capture market share in the injectable antiemetic segment, which had previously been dominated by branded formulations.